Prognosis
While the prognosis continues to improve, there remains significant long-term morbidity and mortality. Overall US mortality prior to introduction of oral antifungals was reported as 2% to 5% per year. Less than half of a 60-patient Italian cohort was alive 25 years after diagnosis.[3][16] In the UK, survival probability among untransplanted patients is 88%, 79%, and 59% at ages 38, 44, and 50 respectively.[34] The widespread use of antimicrobial prophylaxis, and improvements in infection treatment and critical care management, are leading to improved outcomes. However, most patients have a reduced life expectancy.
Use of this content is subject to our disclaimer